IVA Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Inventiva SA's net margin of --. Inventiva SA's return on equity of -- beat DBV Technologies SA's return on equity of --.

Inventiva SA has a consensus price target of $11.13, signalling upside risk potential of 184.78%. On the other hand DBV Technologies SA has an analysts' consensus of $22.63 which suggests that it could grow by 143.52%. Given that Inventiva SA has higher upside potential than DBV Technologies SA, analysts believe Inventiva SA is more attractive than DBV Technologies SA.

Inventiva SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.080, suggesting its less volatile than the S&P 500 by 108.034%.

Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Inventiva SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Inventiva SA's net income of -- is lower than DBV Technologies SA's net income of -$23M. Notably, Inventiva SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 23.84x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -- compared to Inventiva SA's net margin of --. Inventiva SA's return on equity of -- beat Genfit SA's return on equity of --.

Inventiva SA has a consensus price target of $11.13, signalling upside risk potential of 184.78%. On the other hand Genfit SA has an analysts' consensus of $10.17 which suggests that it could grow by 189.17%. Given that Genfit SA has higher upside potential than Inventiva SA, analysts believe Genfit SA is more attractive than Inventiva SA.

Inventiva SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.243%.

Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

Inventiva SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. Inventiva SA's net income of -- is lower than Genfit SA's net income of --. Notably, Inventiva SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 23.84x versus 6.05x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of -- compared to Inventiva SA's net margin of --. Inventiva SA's return on equity of -- beat Innate Pharma SA's return on equity of -72.79%.

Inventiva SA has a consensus price target of $11.13, signalling upside risk potential of 184.78%. On the other hand Innate Pharma SA has an analysts' consensus of $8.01 which suggests that it could grow by 301.4%. Given that Innate Pharma SA has higher upside potential than Inventiva SA, analysts believe Innate Pharma SA is more attractive than Inventiva SA.

Inventiva SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.567%.

Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend.

Inventiva SA quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. Inventiva SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, Inventiva SA's price-to-earnings ratio is -- while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 23.84x versus 11.93x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Nanobiotix SA has a net margin of -- compared to Inventiva SA's net margin of --. Inventiva SA's return on equity of -- beat Nanobiotix SA's return on equity of --.

Inventiva SA has a consensus price target of $11.13, signalling upside risk potential of 184.78%. On the other hand Nanobiotix SA has an analysts' consensus of $7.21 which suggests that it could grow by 120.31%. Given that Inventiva SA has higher upside potential than Nanobiotix SA, analysts believe Inventiva SA is more attractive than Nanobiotix SA.

Inventiva SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanobiotix SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Inventiva SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanobiotix SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inventiva SA pays -- of its earnings as a dividend. Nanobiotix SA pays out -- of its earnings as a dividend.

Inventiva SA quarterly revenues are --, which are smaller than Nanobiotix SA quarterly revenues of --. Inventiva SA's net income of -- is lower than Nanobiotix SA's net income of --. Notably, Inventiva SA's price-to-earnings ratio is -- while Nanobiotix SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inventiva SA is 23.84x versus 3.98x for Nanobiotix SA. Usually stocks with elevated PS ratios are considered overvalued.